Opioids - As enacted, clarifies that a physician licensed in this state is the only healthcare provider authorized to prescribe a buprenorphine product for a FDA-approved use in recovery or medication-assisted treatment; revises criteria for providers not licensed in this state to prescribe a buprenorphine product for the treatment of opioid use disorder. - Amends TCA Title 33; Title 41; Title 53 and Title 63.

Looking ahead

No hearings or votes scheduled.

History

1. 2025
   1. Apr 28Comp. became Pub. Ch. 295Latest
   2. Apr 7Companion House Bill substitutedMajor
   3. Apr 7Sponsor(s) Added.Minor
   4. Apr 4Placed on Senate Regular Calendar for 4/7/2025
   5. Apr 3Senate Reset on calendar for 4/7/2025
   6. Apr 1Placed on Senate Regular Calendar for 4/3/2025
   7. Mar 31Senate Reset on calendar for 4/3/2025
   8. Mar 31Sponsor(s) Added.Minor
   9. Mar 28Placed on Senate Regular Calendar for 3/31/2025
   10. Mar 24Senate Reset on calendar for 3/31/2025
   11. Mar 24Sponsor(s) Added.Minor
   12. Mar 21Placed on Senate Regular Calendar for 3/24/2025
   13. Mar 17Senate Reset on calendar for 3/27/2025
   14. Mar 14Placed on Senate Regular Calendar for 3/17/2025
   15. Mar 11Recommended for passage with amendment/s, refer to Senate Calendar Committee Ayes 9, Nays 0 PNV 0
       • Vote recorded SENATE JUDICIARY COMMITTEE: Recommended for passage with amendment/s, refer to Senate Calendar Committee Ayes 9, Nays 0 PNV 0 3/11/2025 Passed. Result: pass.Upper
   16. Mar 5Placed on Senate Judiciary Committee calendar for 3/11/2025
   17. Feb 25Action deferred in Senate Judiciary Committee to 3/11/2025
   18. Feb 19Placed on Senate Judiciary Committee calendar for 2/25/2025
   19. Feb 12Passed on Second Consideration, refer to Senate Judiciary CommitteeMinor
   20. Feb 10Introduced, Passed on First ConsiderationMinor
   21. Jan 28Filed for introductionIntroduced